SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Masayoshi Miura, Mitsuru Yanai, Yuichiro Fukasawa, Hiroshi Higashiyama, Yosuke Ito, Tohru Tamaki, De novo proteinuria with pathological evidence of glomerulonephritis after everolimus induction, Nephrology, 2014, 19,
  2. 2
    Fuad Shihab, Uwe Christians, Lonnie Smith, Jason R. Wellen, Bruce Kaplan, Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes, Transplant Immunology, 2014, 31, 1, 22

    CrossRef

  3. 3
    Bruce Kaplan, Yasir Qazi, Jason R. Wellen, Strategies for the management of adverse events associated with mTOR inhibitors, Transplantation Reviews, 2014, 28, 3, 126

    CrossRef

  4. 4
    Claudio Ponticelli, The pros and the cons of mTOR inhibitors in kidney transplantation, Expert Review of Clinical Immunology, 2014, 10, 2, 295

    CrossRef

  5. 5
    D. Chhabra, A. Alvarado, P. Dalal, J. Leventhal, C. Wang, N. Sustento-Reodica, N. Najafian, A. Skaro, J. Levitsky, V. Mas, L. Gallon, Impact of Calcineurin-Inhibitor Conversion to mTOR Inhibitor on Renal Allograft Function in a Prednisone-Free Regimen, American Journal of Transplantation, 2013, 13, 11
  6. 6
    V. Ram Peddi, Alexander Wiseman, Kenneth Chavin, Douglas Slakey, Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation, Transplantation Reviews, 2013, 27, 4, 97

    CrossRef